Roche India's Efforts To Curb Fake Drugs Gain Popularity
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - While the global pharmaceutical industry struggles to arrive at a consensus on a new definition of counterfeit drugs, pharmaceutical company Roche India has introduced a cost-effective technology to tackle the problem called 'mass serialisation' that is fast gaining popularity among customers, say company officials
You may also be interested in...
Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News
Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.
Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News
Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.
Roche Gears Up To Launch Actemra In India; Lines Up More Clinical Research
Company has obtained product registration from India’s drug comptroller general, with launch of the RA product expected within the next three months.